Q1 EPS Forecast for Fresenius Medical Care Raised by Analyst

Fresenius Medical Care AG (NYSE:FMS) – Zacks Research boosted their Q1 2025 EPS estimates for shares of Fresenius Medical Care in a report released on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings of $0.44 per share for the quarter, up from their prior forecast of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $2.01 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.19 EPS and FY2027 earnings at $2.07 EPS.

FMS has been the subject of several other research reports. Truist Financial increased their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, StockNews.com raised shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th.

Fresenius Medical Care Stock Performance

FMS opened at $24.29 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average is $23.86 and its 200-day moving average is $22.34. The stock has a market cap of $14.25 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99. Fresenius Medical Care has a twelve month low of $17.93 and a twelve month high of $25.25.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Forum Financial Management LP bought a new position in shares of Fresenius Medical Care during the 4th quarter valued at about $247,000. Vident Advisory LLC boosted its holdings in Fresenius Medical Care by 11.8% during the fourth quarter. Vident Advisory LLC now owns 23,410 shares of the company’s stock worth $530,000 after buying an additional 2,464 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Fresenius Medical Care in the fourth quarter worth approximately $290,000. Point72 Asset Management L.P. bought a new position in shares of Fresenius Medical Care in the fourth quarter valued at $850,000. Finally, Quantinno Capital Management LP boosted its stake in shares of Fresenius Medical Care by 16.0% during the 4th quarter. Quantinno Capital Management LP now owns 127,726 shares of the company’s stock worth $2,892,000 after acquiring an additional 17,648 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.